Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingApr 16, 2025Carvedilol TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0336-2025Class IIOngoingApr 16, 2025Ranolazine Extended-Release Tablets 1000mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0335-2025Class IIOngoingApr 16, 2025Teriflunomide TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0334-2025Class IIOngoingApr 16, 2025Solifenacin Succinate Tablets 5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0333-2025Class IIOngoingApr 16, 2025Saxagliptin Tablets 5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0332-2025Class IIOngoingApr 16, 2025Nitroglycerin Sublingual Tablets 0.3MGCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0331-2025Class IIOngoingApr 16, 2025Lacosamide TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0330-2025Class IIOngoingApr 16, 2025Indomethacin Extended-Release CapsulesCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0329-2025Class IIOngoingApr 16, 2025Metformin Hydrochloride Extended-Release Tablets 1000mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0328-2025Class IIOngoingApr 16, 2025Fluphenazine Hydrochloride Tablets 2.5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0327-2025Class IIOngoingApr 16, 2025Fluphenazine Hydrochloride TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0326-2025Class IIOngoingApr 16, 2025Pravastatin Sodium Tablets 80mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0325-2025Class IIOngoingApr 16, 2025Nitroglycerin Sublingual Tablets 0.4MGCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0324-2025Class IIOngoingApr 16, 2025Rufinamide Tablets 200mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0323-2025Class IIOngoingApr 16, 2025Frovatriptan Succinate Tablets 2.5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0322-2025Class IIOngoingApr 16, 2025Lacosamide Tablets 200mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0321-2025Class IIOngoingApr 16, 2025Gabapentin Tablets 600mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0320-2025Class IIOngoingApr 16, 2025Voriconazole Tablets 50mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0319-2025Class IIOngoingApr 16, 2025Voriconazole Tablets 200 mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0318-2025Class IIOngoingApr 16, 2025Solifenacin Succinate Tablets 10MGCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0317-2025Class IIOngoingApr 16, 2025Propafenone Hydrochloride Extended-Release Capsules 325mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0316-2025Class IIOngoingApr 16, 2025Propafenone Hydrochloride Extended-Release Capsules 225mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0315-2025Class IIOngoingApr 16, 2025Fenofibrate Capsules 67 mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0314-2025Class IITerminatedApr 16, 2025Sofosbuvir and VelpatasvirDefective Container: blister packs not properly sealed resulting in tablets being loose in the carton.Asegua Therapeutics LLC · D-0313-2025Class IIIOngoingApr 16, 2025Gabapentin CapsulesCross ContaminationSun Pharmaceutical Industries Inc · D-0312-2025Class IIIOngoingApr 16, 2025Gabapentin CapsulesCross ContaminationSun Pharmaceutical Industries Inc · D-0311-2025Class IICompletedApr 16, 2025Venlafaxine TabletsPresence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.Zydus Pharmaceuticals (USA) Inc · D-0310-2025Class IIOngoingApr 9, 2025chlorproMAZINE Hydrochloride TabletsCGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.Glenmark Pharmaceuticals Inc., USA · D-0309-2025Class IIOngoingApr 9, 2025Duloxetine Delayed-Release CapsulesCGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.Breckenridge Pharmaceutical, Inc. · D-0308-2025Class IITerminatedApr 9, 2025Voriconazole TabletscGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.Amerisource Health Services LLC · D-0307-2025Class IIOngoingApr 9, 2025Atorvastatin Calcium Tablets USP 40 mgFailed dissolution specifications: lower than specificationsBiocon Pharma Inc · D-0306-2025Class IIIOngoingApr 9, 2025Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthalmic SolutionSub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-110.0% of the label claim.Imprimis NJOF, LLC · D-0305-2025Class IIITerminatedApr 9, 2025Tolterodine Tartrate Extended-Release CapsulesFailed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0304-2025Class IIOngoingApr 2, 20258.4% Sodium Bicarbonate InjectionLack of Assurance of SterilityExela Pharma Sciences LLC · D-0303-2025Class IIOngoingApr 2, 2025[CORRECT FRONT PANEL] Hydrogen Peroxide Topical SolutionLabeling; Label Mixup; some bottles have an incorrect back label indicating 91% Isopropyl AlcoholConsumer Product Partners, LLC · D-0302-2025Class IOngoingApr 2, 2025SinuCleanse Soft Tip NETI POT Nasal Wash SystemMicrobial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureusAscent Consumer Products Inc. · D-0301-2025Class IOngoingApr 2, 2025SinuCleanse Premixed SALINE PACKETSMicrobial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureusAscent Consumer Products Inc. · D-0300-2025Class IOngoingApr 2, 2025SinuCleanse Soft Tip Squeeze Bottle Nasal Wash SystemMicrobial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureusAscent Consumer Products Inc. · D-0299-2025Class IIOngoingApr 2, 2025babyganicsFailed stability specifications: during routine stability monitoring quality concerns were identified. Physical separation for ingredients was observed.Johnson, S C and Son, Inc · D-0298-2025Class IIOngoingApr 2, 2025fentaNYL Citrate PF 200 mcg/100 mLLack of Assurance of SterilityQuVa Pharma, Inc. · D-0297-2025